Bilateral testicular tumors in an infertile man previously treated with follicle-stimulating hormones

Fukushima, Takashi; Kurosawa, Kazuhiro; Sudo, Naoki; Aso, Takayuki; Sugawara, So; Naoe, Michio; Sasaki, Hideo; Yoshida, Hideki

doi:10.1016/j.urology.2004.09.017

Cited by 7 publications

(5 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, 43 of these studies were excluded based on the inclusion and exclusion criteria. The remaining 51 studies included 39 in English [6,8–45], nine in Spanish [46–55], and one in Italian [56]. These studies encompassed a total of 938 men.…”

Section: Resultsmentioning

confidence: 99%

Bilateral testicular germ cell tumours: a systematic review

Zéqui¹,

Costa²,

Santana³

et al. 2012

BJU International

View full text Add to dashboard Cite

What's known on the subject? and What does the study add? Bilateral testicular germ cell tumours (BTGCTs) are rare neoplasms. Most previously published studies consist of case reports or small retrospective case series. Little is known about their epidemiological and clinicopathological characteristics. BTGCT corresponded to 1.82% of testicular tumours. Metachronous disease was about twice as frequent as synchronous disease. The primary tumour histology, chemotherapy use and the interval between metachronous tumours influenced the histology of the second tumour. Overall, synchronous tumours were associated with more advanced disease and presented less favourable survival rates than metachronous tumours. Testicular cancer is the most common tumour in young men. It is known that a second primary contralateral testis tumour may occur in up to 5% of men with a proior tumour. About 35% of these men present with synchronous tumours, and 65% present with metachronous tumours. However there is little data about bilateral testicular germ cell tumours (BTGCT) in the literature and the most published articles are case reports on a small series of men, which makes it difficult to draw conclusions about therapeutic strategies for the treatment of BTGCTs. In fact, current guidelines for the treatment of testicular cancer contain little information related to bilateral disease. Therefore, the aim of our study is to provide a broad overview of BTGCT and to update data focusing on incidence, pathological features, and clinical outcomes of men with BTGCTs. Thus, an extensive review containing 94 studies and more than 50,000 patients was conducted.

show abstract

Section: Resultsmentioning

confidence: 99%

Bilateral testicular germ cell tumours: a systematic review

Zéqui¹,

Costa²,

Santana³

et al. 2012

BJU International

View full text Add to dashboard Cite

show abstract

“…Furthermore, patients with testicular carcinoma present higher levels of cyclin D2, an FSH-dependent stimulatory regulator of mitosis (8). More recently, a case of a bilateral testicular tumor occurring in an infertile man previously treated with FSH was reported, suggesting the hypothesis of an FSH treatment-induced tumor (9).…”

Section: Discussionmentioning

confidence: 99%

Concomitant unilateral and synchronous bilateral testis cancer in azoospermic dizygotic twins: differential management of fertility preservation

Safsaf

Sibert

Cleret

et al. 2011

Fertility and Sterility

View full text Add to dashboard Cite

“…Nevertheless, a previous case report described the development of a seminoma after prolonged FSH and hCG therapy (44). This report concerned a 43-year-old patient with oligozoospermia, normal serum gonadotropins, and an unremarkable ultrasound testicular examination, treated with exogenous FSH for one year.…”

Section: Adverse Effects Of Gonadotropins Therapymentioning

confidence: 92%

Recombinant gonadotropin therapy to improve spermatogenesis in nonobstructive azoospermic patients – A proof of concept study

et al. 2022

View full text Add to dashboard Cite

Purpose: Nonobstructive azoospermia (NOA) associated with primary spermatogenic failure is a common cause of male infertility usually considered untreatable; however, some reports have suggested that hormonal stimulation to boost the intra-testicular testosterone level and spermatogenesis might increase the chance of achieving pregnancy using homologous sperm. Materials and Methods: We report a series of eight NOA males who received long-term treatment with recombinant human chorionic gonadotropin twice a week for spermatogenesis stimulation. Six males received additional recombinant follicle-stimulating hormone (FSH) supplementation 150-225 IU twice weekly. Results: After recombinant gonadotropin therapy, viable spermatozoa were retrieved from the ejaculate in two patients and by testicular sperm aspiration (TESA) in another two subjects. Singleton spermatozoon retrieved from testes were frozen by vitrifi cation on Cell-Sleeper devices. Two live births were obtained after intracytoplasmic sperm injection with ejaculated spermatozoa and one live birth and an ongoing pregnancy using thawed spermatozoa from TESA. Conclusion: Our proof-of-concept study indicates that hormonal therapy with recombinant gonadotropins could be considered in infertile men with NOA as an alternative to sperm donation. Large-scale studies are needed to substantiate hormone stimulation therapy with recombinant gonadotropins in routine clinical practice for this severe form of male infertility.

show abstract

Bilateral testicular tumors in an infertile man previously treated with follicle-stimulating hormones

Cited by 7 publications

References 13 publications

Bilateral testicular germ cell tumours: a systematic review

Bilateral testicular germ cell tumours: a systematic review

Concomitant unilateral and synchronous bilateral testis cancer in azoospermic dizygotic twins: differential management of fertility preservation

Recombinant gonadotropin therapy to improve spermatogenesis in nonobstructive azoospermic patients – A proof of concept study

Contact Info

Product

Resources

About